GleamWall
中文EN

MAZE Maze Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1842295 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-20.1%
TTM EPS YoY32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-37.5%
ROA-32.4%
ROIC (approx.)-69.0%
Asset turnover—

Leverage & solvency

Liabilities / assets16.2%
Debt / equity0.09x
Current ratio14.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$20.00M——$0—$0
R&D expense$40.22M$34.94M$34.15M$27.57M$25.19M$28.11M$27.58M$22.22M
SG&A expense$11.30M$13.10M$12.40M$10.49M$7.78M$8.37M$7.82M$7.51M
Operating income-$51.52M-$48.03M-$26.55M-$38.06M-$32.97M-$36.47M-$35.40M-$29.73M
Interest expense$975,000$931,000$866,000—————
Pretax income———-$34.57M-$30.09M-$33.68M-$32.79M-$29.85M
Income tax———$0$0$0—-$275,000
Net income-$47.97M-$44.73M-$24.21M-$34.57M-$30.09M-$33.68M-$32.79M-$29.58M
EBITDA-$51.13M-$47.64M-$26.11M-$37.56M-$32.39M-$35.83M-$34.72M-$29.02M
EPS (basic)-0.79-0.76-0.45—-0.66-0.77-1.15—
EPS (diluted)-0.79-0.76-0.45—-0.66-0.77-1.15—
Weighted avg. shares (diluted)60.86M59.00M53.90M—45.78M43.80M28.63M—
Balance sheet
Cash & equivalents$154.16M$202.64M$198.77M$189.25M$316.77M$264.54M$294.37M$197.90M
Short-term investments$235.50M$208.44M$153.62M$152.67M$67.16M———
Receivables——$20.00M—————
Current assets$400.10M$420.42M$379.78M$349.72M$391.30M$271.15M$299.71M$201.67M
PP&E, net$4.35M$4.39M$4.68M$5.04M$5.54M$6.01M$6.31M$6.67M
Total assets$511.56M$531.62M$419.71M$397.13M$422.06M$303.52M$332.84M$240.54M
Current liabilities$28.30M$22.96M$21.24M$22.56M$22.11M$19.90M$18.62M$20.67M
Short-term debt$0$0$0—————
Long-term debt$39.12M$38.96M$38.83M—————
Total debt$39.12M$38.96M$38.83M—————
Total liabilities$83.01M$78.50M$78.01M$42.16M$42.62M$41.28M$40.77M$43.64M
Shareholders' equity$428.55M$453.12M$341.70M$354.97M$379.44M$262.24M$292.07M-$311.18M
Net debt-$115.03M-$163.68M-$159.93M—————
Shares outstanding56.45M55.50M49.74M49.34M48.08M43.85M43.80M2.45M
Cash flow statement
Operating cash flow-$32.84M-$15.05M-$39.11M-$27.73M-$24.64M-$30.05M-$29.52M-$22.45M
Capital expenditure$288,000$107,000$93,000$34,000$68,000$393,000$299,000$605,000
Free cash flow-$33.13M-$15.16M-$39.21M-$27.76M-$24.71M-$30.45M-$29.82M-$23.06M
Investing cash flow-$31.41M-$128.51M$6.28M-$103.39M-$66.88M-$393,000-$299,000-$605,000
Financing cash flow$15.77M$147.44M$42.36M$3.59M$143.76M$612,000$127.38M$70.26M
Depreciation & amortization$385,000$391,000$444,000$499,000$571,000$649,000$684,000$705,000
Stock-based compensation$8.54M$9.19M$7.11M$6.07M$3.86M$3.24M$3.23M$2.85M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.